EP 7041

Drug Profile

EP 7041

Alternative Names: EP-7041

Latest Information Update: 16 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator eXIthera Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Small molecules
  • Mechanism of Action Factor XIa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

  • 01 May 2017 eXIthera Pharmaceuticals completes a phase I trial in Thrombosis (In volunteers) in Australia (IV) (NCT02914353)
  • 01 Jul 2016 Phase-I clinical trials in Thrombosis (In volunteers) in Australia (IV) (NCT02914353)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top